Targeting complement component 5a promotes vascular integrity and limits airway remodeling

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 15, 2013, Pages 6061-6066

  Khan, Mohammad A ^a   Maasch, Christian ^b   Vater, Axel ^b   Klussmann, Sven ^b   Morser, John ^a,c   Leung, Lawrence L ^a,c   Atkinson, Carl ^d   Tomlinson, Stephen ^d   Heeger, Peter S ^e   Nicolls, Mark R ^a,c  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b NOXXON PHARMA AG   (Germany)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d MOUNT SINAI HOSPITAL   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alloimmunity; Bronchiolitis obliterans syndrome; Chronic rejection; Fibrosis; Hypoxia

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT COMPONENT C5A; NOX D 19; THROMBIN; UNCLASSIFIED DRUG;

AIRWAY REMODELING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; GRAFT RECIPIENT; IMMUNOSUPPRESSIVE TREATMENT; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MICROVASCULAR ISCHEMIA; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; T LYMPHOCYTE; TISSUE OXYGENATION; VASODILATATION;

AIRWAY REMODELING; ANIMALS; ANOXIA; ANTIGENS, CD31; BRONCHIOLITIS OBLITERANS; COMPLEMENT C3; COMPLEMENT C5A; FIBROSIS; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROCIRCULATION; OXYGEN; PERFUSION; THROMBIN; TRANSPLANTATION, HOMOLOGOUS;

EID: 84876033719     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1217991110     Document Type: Article

References (34)

1. Bishop GA, Waugh JA, Landers DV, Krensky AM, Hall BM (1989) Microvascular destruction in renal transplant rejection. Transplantation 48(3):408-414.
2. Matsumoto Y, McCaughan GW, Painter DM, Bishop GA (1993) Evidence that portal tract microvascular destruction precedes bile duct loss in human liver allograft rejection. Transplantation 56(1):69-75.
3. Luckraz H, et al. (2004) Microvascular changes in small airways predispose to obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant 23(5):527-531.
4. Luckraz H, et al. (2006) Is obliterative bronchiolitis in lung transplantation associated with microvascular damage to small airways? Ann Thorac Surg 82(4):1212-1218.
5. Babu AN, et al. (2007) Microvascular destruction identifies murine allografts that cannot be rescued from airway fibrosis. J Clin Invest 117(12):3774-3785.
6. Jiang X, et al. (2011) Adenovirus-mediated HIF-1α gene transfer promotes repair of mouse airway allograft microvasculature and attenuates chronic rejection. J Clin Invest 121(6):2336-2349.
7. Sato M, Keshavjee S (2008) Bronchiolitis obliterans syndrome: Alloimmune-dependent and -independent injury with aberrant tissue remodeling. Semin Thorac Cardiovasc Surg 20(2):173-182.
8. Khan MA, et al. (2011) CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Circ Res 109(11):1290-1301.
9. Keshavjee S, Davis RD, Zamora MR, de Perrot M, Patterson GA (2005) A randomized, placebo-controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings. J Thorac Cardiovasc Surg 129(2):423-428.
10. Huber-Lang M, et al. (2006) Generation of C5a in the absence of C3: A new complement activation pathway. Nat Med 12(6):682-687.
11. Segal JB, et al. (2001) Coagulation markers predicting cardiac transplant rejection. Transplantation 72(2):233-237.
12. Klussmann S, Nolte A, Bald R, Erdmann VA, Fürste JP (1996) Mirror-image RNA that binds D-adenosine. Nat Biotechnol 14(9):1112-1115.
13. Purschke WG, Eulberg D, Buchner K, Vonhoff S, Klussmann S (2006) An L-RNA-based aquaretic agent that inhibits vasopressin in vivo. Proc Natl Acad Sci USA 103(13):5173-5178.
14. Darisipudi MN, et al. (2011) Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. Am J Pathol 179(1):116-124.
15. Vater A, Jarosch F, Buchner K, Klussmann S (2003) Short bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach: tailored-SELEX. Nucleic Acids Res 31(21):e130.
16. Greinacher A, Warkentin TE (2008) The direct thrombin inhibitor hirudin. Thromb Haemost 99(5):819-829.
17. Raedler H, et al. (2011) Anti-complement component C5 mAb synergizes with CTLA4Ig to inhibit alloreactive T cells and prolong cardiac allograft survival in mice. Am J Transplant 11(7):1397-1406.
18. Rothberger H, Barringer M, Meredith J (1984) Increased tissue factor activity of monocytes/macrophages isolated from canine renal allografts. Blood 63(3):623-628.
19. Lin CC, et al. (2010) Recipient tissue factor expression is associated with consumptive coagulopathy in pig-to-primate kidney xenotransplantation. Am J Transplant 10(7):1556-1568.
20. Ji M, et al. (2011) The importance of tissue factor expression by porcine NICC in triggering IBMIR in the xenograft setting. Transplantation 91(8):841-846.
21. Hölschermann H, et al. (2000) Hirudin reduces tissue factor expression and attenuates graft arteriosclerosis in rat cardiac allografts. Circulation 102(3):357-363.
22. Amara U, et al. (2010) Molecular intercommunication between the complement and coagulation systems. J Immunol 185(9):5628-5636.
23. Rutkowski MJ, et al. (2010) The complement cascade as a mediator of tissue growth and regeneration. Inflamm Res 59(11):897-905.
24. Polley MJ, Nachman R (1978) The human complement system in thrombin-mediated platelet function. J Exp Med 147(6):1713-1726.
25. Wetsel RA, Kolb WP (1983) Expression of C5a-like biological activities by the fifth component of human complement (C5) upon limited digestion with noncomplement enzymes without release of polypeptide fragments. J Exp Med 157(6):2029-2048.
26. Krisinger MJ, et al. (2012) Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood 120(8):1717-1725.
27. Ward PA, Hill JH (1970) C5 chemotactic fragments produced by an enzyme in lysosomal granules of neutrophils. J Immunol 104(3):535-543.
28. Huber-Lang M, et al. (2002) Generation of C5a by phagocytic cells. Am J Pathol 161(5):1849-1859.
29. Zwirner J, Fayyazi A, Götze O (1999) Expression of the anaphylatoxin C5a receptor in non-myeloid cells. Mol Immunol 36(13-14):877-884.
30. Allegretti M, et al. (2005) Targeting C5a: Recent advances in drug discovery. Curr Med Chem 12(2):217-236.
31. Woodruff TM, Nandakumar KS, Tedesco F (2011) Inhibiting the C5-C5a receptor axis. Mol Immunol 48(14):1631-1642.
32. DiScipio RG, Daffern PJ, Jagels MA, Broide DH, Sriramarao P (1999) A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo. J Immunol 162(2):1127-1136.
33. Tsuji RF, et al. (2000) Early local generation of C5a initiates the elicitation of contact sensitivity by leading to early T cell recruitment. J Immunol 165(3):1588-1598.
34. Khan MA, Dhillon G, Jiang X, Lin YC, Nicolls MR (2012) New methods for monitoring dynamic airway tissue oxygenation and perfusion in experimental and clinical transplantation. Am J Physiol Lung Cell Mol Physiol 303(10):L861-L869.